MASLD, formerly known as non-alcoholic fatty liver disease, affects a substantial and growing proportion of the global population, closely tracking the worldwide rise in obesity, type 2 diabetes, and metabolic syndrome. In its early and middle stages, the condition is still reversible with timely clinical intervention. Left unmanaged, however, it can progress to inflammation, fibrosis, cirrhosis, and ultimately liver failure or cancer. Precisely because the window for intervention is widest early in the disease, identifying new molecular targets has become a major priority for hepatology researchers. The new study, led by Tiansu Lv, Hongshan Dai, Shihu Zhang, and colleagues under the co-corresponding authorship of Feng Zhang and Xiqiao Zhou at Jiangsu Province Hospital of Chinese Medicine and collaborating institutions in Nanjing, offers one of the most detailed multi-scale portraits to date of what goes wrong inside the liver microenvironment during MASLD—and introduces an entirely new cell type into the picture.

What makes the study technically striking is the layered, multi-platform strategy the team employed. Rather than relying on a single analytical technique, the researchers combined high-dimensional single-cell immunophenotyping with mass spectrometry–based proteomics, phosphoproteomics, and spatial proteomics, followed by mechanistic validation in cell models. The first stage used cytometry by time of flight, or CyTOF, a technology that tags cells with heavy-metal-conjugated antibodies and measures dozens of protein markers simultaneously in each individual cell by mass spectrometry. This allowed the team to map the immune landscape of the MASLD liver in unprecedented detail, distinguishing cell populations that conventional flow cytometry would collapse into indistinguishable groups.

The CyTOF analysis produced a clear and consequential signal: myeloid-derived cells—the broad family of innate immune cells that includes monocytes, macrophages, and dendritic cells—were significantly expanded in MASLD liver tissue. That expansion made the myeloid compartment the obvious next target. The team therefore sorted these key cell populations and subjected them to liquid chromatography–tandem mass spectrometry (LC–MS/MS) with label-free quantification, probing both the total proteome and the phosphoproteome—the complete set of phosphorylated proteins that reveals which signaling pathways are switched on or off inside the cells. Phosphoproteomics is particularly powerful here because phosphorylation events are the molecular currency of cellular communication; mapping them provides a direct readout of pathway activity rather than mere protein abundance.

The proteomic and phosphoproteomic analyses converged on a surprising culprit: amino acid metabolism. Two metabolic pathways emerged as severely impaired in the myeloid cells of MASLD patients. The first was the glycine metabolic pathway, regulated by the enzyme alanine-glyoxylate aminotransferase 2, or AGXT2. The second was the proline metabolic pathway, regulated by pyrroline-5-carboxylate reductase 3, or PYCR3, an enzyme that catalyzes the final step in proline biosynthesis, converting Δ1-pyrroline-5-carboxylate into proline. Glycine and proline may sound like obscure biochemical players, but both are deeply intertwined with cellular health: glycine feeds glutathione synthesis, the cell’s master antioxidant defense, while proline is essential for protein synthesis, redox balance, and—critically for the liver—collagen production by fibrotic cells.

To find out where in the diseased liver these metabolic defects were concentrated, the researchers turned to imaging mass cytometry, or IMC. This spatial proteomics technique combines the multiplexing power of mass cytometry with high-resolution tissue imaging: tissue sections, including formalin-fixed paraffin-embedded clinical samples, are stained with panels of metal-tagged antibodies, and a laser ablates the tissue pixel by pixel while a mass spectrometer records the metal signal at each position. The result is a map showing, at single-cell resolution, which cells express which dozens of proteins—and, crucially, which cells sit next to which. Applying IMC to liver biopsies from MASLD patients and healthy controls, the team homed in on the two metabolic enzymes and made their central discovery: a subset of macrophages that were negative for both AGXT2 and PYCR3.

These AGXT2−PYCR3− macrophages were significantly enriched in MASLD livers compared with healthy tissue. But abundance alone was not the striking part. The spatial analysis showed that these cells exhibited high colocalization with inflammatory cells and fibrotic cells—they were physically clustered in the exact neighborhoods where inflammation and scarring unfold. Within the macrophage compartment, the team compared different dysregulated subsets and found that the M2-type dysregulated cluster (designated M2-C1), which encompasses the AGXT2−PYCR3− population, displayed even stronger pro-inflammatory and pro-fibrotic potential than the dysregulated M1 subset (M1-C3). This is notable because M2 macrophages are classically considered the “reparative,” anti-inflammatory arm of the macrophage family; the finding that a dysregulated M2-like subset could be more inflammatory and fibrogenic than its M1 counterpart underscores how profoundly amino acid metabolic failure rewires immune cell identity.

To move beyond correlation, the researchers built in vitro models using both human THP-1-derived macrophages and murine RAW264.7 macrophages, in which AGXT2 and PYCR3 expression was knocked down using siRNA and shRNA approaches, recapitulating the metabolic defect seen in patient tissue. The results were unambiguous. Macrophages lacking AGXT2 and PYCR3 showed enhanced proliferation and migration—behaviors consistent with aggressive tissue infiltration. They secreted higher levels of inflammatory cytokines and chemokines, the signaling molecules that recruit further immune cells to sites of damage. They also released elevated amounts of classic fibrotic proteins and exerted a strong inductive effect on hepatic fibrotic cells, essentially coaching other cells in the liver to adopt a scar-producing phenotype. A key biochemical clue accompanied these observations: intracellular glutathione, or GSH, was downregulated in the defective macrophages, linking the metabolic lesion to a collapse in antioxidant capacity and the oxidative stress that drives inflammation.

The mechanistic dissection revealed which signaling circuits were responsible. The heightened inflammatory output traced to activation of the NF-κB pathway and the MAPK/AP-1 pathway—two of the most important transcriptional programs governing inflammatory gene expression. The pro-fibrotic behavior, meanwhile, was driven by phosphorylation of SMAD3 at threonine 8 within the TGFβ signaling axis, the canonical pathway that instructs cells to produce collagen and other extracellular matrix components. In other words, losing two amino acid metabolic enzymes in macrophages was sufficient to switch on the master regulators of both inflammation and fibrosis—the twin engines of MASLD progression.

Perhaps the most clinically tantalizing result came next. When the researchers supplemented the defective macrophage cultures with the corresponding amino acids—restoring the glycine and proline supply that the broken metabolic pathways could no longer adequately generate—the aberrant phenotypes were effectively rescued. Proliferation, migration, cytokine secretion, and fibrotic signaling all receded, accompanied by reversal of the abnormal NF-κB, MAPK/AP-1, and p-SMAD3/TGFβ pathway activation. While amino acid supplementation in a culture dish is a very long way from a therapy in a patient—the study’s in vitro findings will require extensive validation, including animal studies and ultimately clinical trials—the result establishes an initial, mechanistic link between amino acid metabolism and early-to-middle-stage MASLD, and it suggests a conceptual framework in which metabolic support of immune cells might blunt disease progression.

The work also carries methodological significance for the field. By integrating CyTOF, quantitative proteomics, phosphoproteomics, and IMC within a single study design, the researchers demonstrated a pipeline that moves fluidly from unbiased discovery of cellular changes to spatial localization in actual patient tissue to mechanistic confirmation in controlled models. This end-to-end approach addresses a persistent weakness in single-cell biology, where discoveries made in dissociated cell suspensions often fail to be anchored in their true tissue context. Here, the spatial data were essential: without IMC, the intimate physical association between AGXT2−PYCR3− macrophages, inflammatory cells, and fibrotic cells would have remained invisible.

The study, conducted with ethical approval from Jiangsu Province Hospital of Chinese Medicine and published open access, was funded by the National Natural Science Foundation of China and provincial research programs. The authors note that the term MASLD is used throughout to avoid stigmatizing patients, and that no animal experiments were involved in the research. As MASLD prevalence continues to climb worldwide, the identification of AGXT2−PYCR3− macrophages offers researchers a new cellular target, a new biomarker candidate, and a fresh biochemical hypothesis—all pointing toward the possibility that the road to liver fibrosis runs, at least in part, through broken amino acid metabolism in the immune cells that patrol the hepatic frontier.

Biliary atresia is a life-threatening neonatal condition characterized by progressive inflammation and obstruction of the bile ducts, ultimately leading to liver fibrosis, cirrhosis, and the dire need for liver transplantation in affected infants. Despite decades of research, the complex interplay of genetic, environmental, and immunological factors contributing to the disease’s pathogenesis remains incompletely understood. The discovery of SULT2B1’s role introduces a new biochemical player in the intricate puzzle of this progressive cholangiopathy.

SULT2B1 belongs to the sulfotransferase enzyme family, responsible for transferring sulfate groups to hydroxyl-containing substrates, a process essential in modifying steroids, lipids, and xenobiotics. The study reveals an upregulation of SULT2B1 expression in cholangiocytes undergoing EMT—a biological process where epithelial cells lose their polarity and adhesion properties, transforming into a mesenchymal phenotype with enhanced motility and invasiveness. This transition is a well-recognized contributor to fibrosis and tissue remodeling across various organ systems but has been underexplored in biliary atresia.

The research team utilized a combination of human tissue samples from biliary atresia patients and sophisticated in vitro models simulating cholangiocyte behavior. Their molecular analyses demonstrated that elevated SULT2B1 levels correlate strongly with markers of EMT, including decreased E-cadherin and increased vimentin expression, hallmark indicators of epithelial de-differentiation and mesenchymal transition. This correlation intimates that SULT2B1 may serve as more than a passive biomarker but as an active mediator driving phenotypic changes that exacerbate bile duct obliteration.

Beyond correlative findings, Balfour-Lynn and Dhawan’s experiments hinted at the mechanistic pathways involved. One compelling avenue is the modulation of signaling cascades such as TGF-β (transforming growth factor-beta), a known EMT inducer in various fibrotic diseases. They posit that SULT2B1 enzymatic activity could enhance TGF-β signaling or alter the bioavailability of sulfated sterols that modulate cellular responses, creating a feedback loop amplifying the EMT process in cholangiocytes.

This biochemical mechanism carries profound implications. Understanding the role of SULT2B1 enriches the molecular map of biliary atresia’s progression, suggesting the enzyme functions as a fulcrum tipping the balance toward irreversible ductal damage and fibrosis. Consequently, targeting SULT2B1 or its downstream pathways offers a tantalizing strategy to arrest or even reverse the pathological EMT events before irreversible bile duct loss.

Clinically, this discovery addresses a glaring therapeutic gap in biliary atresia management. Current intervention relies heavily on the Kasai portoenterostomy procedure to restore bile flow, a technique that, while lifesaving, fails to halt the progressive fibrogenic processes leading to liver failure in many cases. The prospect of pharmacological agents modulating SULT2B1 activity highlights the potential for adjunct therapies that might improve long-term outcomes by directly interfering with disease mechanisms rather than merely alleviating symptoms.

There is also broader relevance in understanding the molecular interplay between sulfotransferase enzymes and EMT across different fibrotic diseases. If SULT2B1’s promotive role in EMT extends beyond cholangiocytes, it may represent a universal therapeutic target in organ fibrosis, offering insights into treatment approaches for conditions such as idiopathic pulmonary fibrosis or systemic sclerosis.

However, the road from discovery to clinical application is fraught with challenges. Any therapeutic modulation of SULT2B1 must consider its physiological roles in steroid metabolism and detoxification, emphasizing the need for highly specific inhibitors that minimize off-target effects. Additionally, the timing of intervention will be crucial; targeting EMT in the earliest disease phase could confer the greatest benefit, necessitating improvements in early diagnosis and disease monitoring.

The study further raises fascinating questions about the regulation of SULT2B1 expression itself. Elucidating upstream genetic or epigenetic factors triggering its aberrant activation in cholangiocytes might uncover novel biomarkers for early biliary atresia detection or even preventive avenues in genetically predisposed populations.

Moreover, the role of environmental triggers or infectious agents, long postulated contributors to biliary atresia initiation, could likely converge on pathways regulating SULT2B1 expression or activity. This intersection remains an exciting frontier for future research, potentially integrating pathogen-host interactions with intracellular signaling alterations underpinning EMT.

In terms of diagnostic advancements, SULT2B1 expression patterns might serve as valuable histological or molecular markers distinguishing aggressive disease phenotypes. This information could inform prognostication and tailor clinical decision-making, especially in ambiguous or early cases where the disease trajectory is unpredictable.

The work of Balfour-Lynn and Dhawan thus marks a seminal moment in pediatric hepatology, blending biochemistry, cell biology, and clinical insight into a multifaceted narrative of biliary atresia pathogenesis. As researchers worldwide digest these findings, the ripple effects may inspire a paradigm shift from reactive surgical treatments toward precision medicine approaches combating the molecular drivers of this fatal disease.

Continued investigations will ideally extend these results into animal models and eventually clinical trials to validate the safety and efficacy of potential SULT2B1 inhibitors or modulators. Such translational steps are critical to transforming this scientific insight into tangible benefits for infants suffering from biliary atresia, a group currently facing limited options and bleak prognoses.

In the face of complex diseases such as biliary atresia, where early tissue remodeling predicates irreversible damage, insights like those provided by SULT2B1’s role offer renewed hope. They point to the possibility that a molecular “baby step” may, in fact, represent a giant leap toward unraveling the genotype-phenotype nexus dictating disease severity and uncovering novel therapeutic pathways.

As this research permeates clinical and scientific discourse, it stands as a sterling example of how deep molecular elucidation can illuminate pathophysiology, reshape treatment paradigms, and ultimately improve outcomes in pediatric liver diseases. The journey from bench to bedside is long, but studies like this propel us decisively forward.

Subject of Research:
The role of SULT2B1 enzyme in promoting cholangiocyte epithelial-mesenchymal transition in the pathogenesis of biliary atresia.

Article Title:
SULT2B1 promotes cholangiocyte epithelial-mesenchymal transition in biliary atresia: one baby step or a giant leap in the pathogenesis of biliary atresia?

Article References:
Balfour-Lynn, R.E., Dhawan, A. SULT2B1 promotes cholangiocyte epithelial-mesenchymal transition in biliary atresia: one baby step or a giant leap in the pathogenesis of biliary atresia?. Pediatr Res (2026). https://doi.org/10.1038/s41390-025-04688-5

Image Credits: AI Generated

DOI:
https://doi.org/10.1038/s41390-025-04688-5